# Addex Probability Of Bankruptcy

ADXN Stock | USD 0.70 0.05 7.69% |

Addex | Probability Of Bankruptcy |

**M**, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (20.7

**M**).

## Addex Probability Of Bankruptcy Analysis

Addex Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

More About Probability Of Bankruptcy | All Equity Analysis

2020 | 2021 | 2022 | 2023 (projected) | |

Interest Expense | 650.63 K | 63.01 K | 313.26 K | 310.16 K |

Gross Profit | 3.61 M | 2.92 M | 1.42 M | 2.16 M |

Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Addex Therapeutics Probability Of Bankruptcy | Over 81% |

Most of Addex Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Addex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Addex Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Addex Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Addex Therapeutics financial health.

Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share(2.41) | Revenue Per Share0.192 | Quarterly Revenue Growth0.493 | Return On Assets(0.83) | Return On Equity(1.90) |

The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Addex Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Addex Therapeutics is extremely important. It helps to project a fair market value of Addex Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Addex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Addex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Addex Therapeutics' interrelated accounts and indicators.

**Click cells**to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition |

Based on the latest financial disclosure, Addex Therapeutics has a Probability Of Bankruptcy of 81%. This is 87.11% higher than that of the Healthcare sector and 47.7% higher than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 103.36% lower than that of the firm.

## Addex Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Addex Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Addex Therapeutics could also be used in its relative valuation, which is a method of valuing Addex Therapeutics by comparing valuation metrics of similar companies.Addex Therapeutics is currently under evaluation in probability of bankruptcy category among related companies.

## Addex Therapeutics Main Bankruptcy Drivers

2018 | 2019 | 2020 | 2021 | 2022 | 2023 (projected) | ||

Total Liabilities | 2.97 M | 7.5 M | 5.57 M | 5.61 M | 3.37 M | 4.35 M | |

Current Liabilities | 2.33 M | 5.68 M | 3.62 M | 4.13 M | 3.28 M | 3.71 M | |

Total Assets | 42.21 M | 33.03 M | 20.18 M | 22.54 M | 8.28 M | 8.5 M | |

Current Assets | 42.15 M | 32.39 M | 19.49 M | 21.94 M | 7.83 M | 8.03 M | |

Net Cash Flow from Operations | 1.75 M | (9.48 M) | (12.18 M) | (14.71 M) | (16.44 M) | (16.87 M) |

## Addex Fundamentals

Return On Equity | (1.90) % | |||

Return On Asset | (0.83) % | |||

Current Valuation | 3.12 M | |||

Shares Outstanding | 14.81 M | |||

Shares Owned by Institutions | 18.00 % | |||

Number of Shares Shorted | 673.14 K | |||

Price to Book | 1.41 X | |||

Price to Sales | 10.28 X | |||

Revenue | 1.42 M | |||

Gross Profit | 1.44 M | |||

EBITDA | (20.17 M) | |||

Net Income | (20.8 M) | |||

Cash and Equivalents | 8.81 M | |||

Cash per Share | 1.40 X | |||

Total Debt | 336.95 K | |||

Debt to Equity | 0.049 % | |||

Current Ratio | 2.55 X | |||

Book Value Per Share | 0.38 X | |||

Cash Flow from Operations | (16.44 M) | |||

Short Ratio | 0.71 X | |||

Earnings Per Share | (2.41) X | |||

Number of Employees | 24 | |||

Beta | 1.67 | |||

Market Capitalization | 11.14 M | |||

Total Asset | 8.28 M | |||

Retained Earnings | (349.86 M) | |||

Working Capital | 4.55 M | |||

Current Asset | 32.02 M | |||

Current Liabilities | 4.82 M | |||

Z Score | -46.5 | |||

Net Asset | 8.28 M |

## About Addex Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Addex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Addex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Addex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. Addex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Addex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Addex Therapeutics' short interest history, or implied volatility extrapolated from Addex Therapeutics options trading.

## Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.### Moving together with Addex Stock

+ | 0.68 | KA | Kineta Inc | Symbol Change | PairCorr | ||

+ | 0.8 | YS | YS Biopharma | Buyout Trend | PairCorr | ||

+ | 0.74 | VACC | Vaccitech PLC ADR | Fiscal Quarter End 30th of June 2023 | PairCorr |

### Moving against Addex Stock

- | 0.46 | VBLT | Vascular Biogenics | Fiscal Quarter End 30th of June 2023 | PairCorr | ||

- | 0.46 | VECT | VectivBio Holding | Report 19th of July 2023 | PairCorr |

The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.

The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Addex Therapeutics Piotroski F Score and Addex Therapeutics Altman Z Score analysis. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

## Complementary Tools for Addex Stock analysis

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |

Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |

Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |

Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |

My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |

Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |

Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |

Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |

Transaction History View history of all your transactions and understand their impact on performance | |

Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |

Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share(2.41) | Revenue Per Share0.192 | Quarterly Revenue Growth0.493 | Return On Assets(0.83) | Return On Equity(1.90) |

The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.